Michael J. Vergare, MD
Professor & Chair,
Department of Psychiatry
& Human Behavior
Objectives & Philosophy
The primary objective of our psychosomatic medicine fellowship training program is to train clinicians in the specialty of psychosomatic medicine and to allow the fellow to develop into an independent practicing psychosomatic medicine physician. Additionally, we aim to develop future academicians and to develop the psychosomatic medicine leaders of the future. Our program is academically based and is designed to provide a well-balanced educational training experience that fulfills the requirements established by the Residency Review Committee for Psychosomatic Medicine. We are interested in training competent and caring clinicians while providing an environment that will nurture intellectual curiosity, support personal growth and prepare fellows for a successful professional career.
We believe that this comprehensive education is attained through diverse clinical and scholarly experiences. Our curriculum and experience is designed to produce highly qualified physicians who have a superior base of medical knowledge, excellent procedural and therapeutic skills and the ability to apply these skills in the practice of psychosomatic medicine.
After graduation, our fellows may practice in the city or assume academic consultation-liaison faculty positions. As our program provides experiences in education, research, and other academic pursuits, it allows ample opportunity to pursue a variety of career paths as clinicians, educators and/or researchers. Fellows also are prepared to assume leadership and administrative positions or to continue their education in a variety of fellowships.
Michael J. Vergare, MD
Madeleine Becker, MD
Program Director, Psychosomatic Medicine Fellowship
1020 Sansom Street
Philadelphia, PA 19107
- 6 'd's: Next steps after an insufficient antipsychotic response
- Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer
- Erratum: Safety and tolerability of levomilnacipran ER in major depressive disorder: Results from an open-label, 48-Week extension study(Clin Drug Investig (2013):33:761-771 DOI 10.1007/s40261-013-0126-5)
- Safety and tolerability of levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study
- Catatonia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Report of Two Cases and a Review